Clinical Trials

We are working with multiple collaborators on studies in several cancer types, with an emphasis on pancreatic cancer.

As a follow-up to FDA’s breakthrough device designation for our pancreatic cancer test panel, Bluestar Genomics is currently conducting two large clinical studies at multiple sites across the United States. Learn more about study design, patient criteria, and enrollment:

Tracking Epigenomic Signals To Detect Cancer Early